AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 23372613 — intervention group
Group type: COMPARATOR
Intervention: Centers with more than 50 patients
Number of subjects: 8121
Study 23372613 — intervention group
Group type: COMPARATOR
Intervention: University hospitals
Number of subjects: 8121
Study 23372613 — intervention group
Group type: COMPARATOR
Intervention: Non-university hospitals
Number of subjects: 8121
Study 23372613 — intervention group
Group type: COMPARATOR
Intervention: Medical practices specializing in hematology and oncology
Number of subjects: 8121
Study 19347940 — intervention group
Group type: EXPERIMENTAL
Intervention: Low power laser (InGaAlP laser, 660 nm/40 mW/6 J cm(‐2)/0.24 J per point), three times a week
Number of subjects: 39
Study 19347940 — intervention group
Group type: EXPERIMENTAL
Intervention: Combined high and low power lasers (GaAlAs laser, 808 nm, 1 W/cm(2)), three times a week
Number of subjects: 39
Study 19347940 — intervention group
Group type: EXPERIMENTAL
Intervention: Low power laser (InGaAlP laser, 660 nm/40 mW/6 J cm(‐2)/0.24 J per point), once a week
Number of subjects: 39
Study 19347940 — intervention group
Group type: EXPERIMENTAL
Intervention: Combined low/high power laser therapy
Number of subjects: 39
Study 17766671 — intervention group
Group type: EXPERIMENTAL
Intervention: Partners in Caregiving in a Special Care Environment intervention
Number of subjects: 772
Study 17766671 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 772
Study 15006213 — intervention group
Group type: EXPERIMENTAL
Intervention: Asynchronous teleconsultation (telemedicine group)
Number of subjects: 208
Study 15006213 — intervention group
Group type: COMPARATOR
Intervention: Traditional outpatient consultation (control group)
Number of subjects: 208
Study 11440275 — intervention group
Group type: EXPERIMENTAL
Intervention: Plasma adrenomedullin concentrations in patients with pheochromocytoma (37.9 +/- 6 pg/ml)
Number of subjects: 10
Study 11440275 — intervention group
Group type: EXPERIMENTAL
Intervention: Plasma adrenomedullin concentrations before and after tumor removal in patients with pheochromocytoma
Number of subjects: 10
Study 11440275 — intervention group
Group type: EXPERIMENTAL
Intervention: Correlation of plasma adrenomedullin levels with plasma noradrenaline in patients with pheochromocytoma
Number of subjects: 10
Study 11440275 — intervention group
Group type: EXPERIMENTAL
Intervention: Plasma adrenomedullin levels during surgery in four patients
Number of subjects: 10
Study 9763725 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-dose phenobarbital given daily for 3-7 days in conjunction with malaria therapy (artesunate or quinine + tetracycline)
Number of subjects: 0
Study 9763725 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-dose phenobarbital with 5-day artesunate regimen
Number of subjects: 0
Study 9763725 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-dose phenobarbital with quinine-tetracycline regimen
Number of subjects: 0
Study 9763725 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-dose phenobarbital with dosing every 24 hours (artesunate)
Number of subjects: 0
Study 8311270 — intervention group
Group type: EXPERIMENTAL
Intervention: 70 mL of 0.25% ropivacaine
Number of subjects: 66
Study 8311270 — intervention group
Group type: EXPERIMENTAL
Intervention: 70 mL of 0.125% ropivacaine
Number of subjects: 66
Study 8311270 — intervention group
Group type: COMPARATOR
Intervention: Saline (control group)
Number of subjects: 66
Study 3414926 — intervention group
Group type: EXPERIMENTAL
Intervention: Use of an oropharyngeal airway
Number of subjects: 88
Study 3414926 — intervention group
Group type: COMPARATOR
Intervention: No use of an oropharyngeal airway (control group)
Number of subjects: 88
Study 29592840 — intervention group
Group type: EXPERIMENTAL
Intervention: Doravirine 100 mg once daily plus two NRTIs (tenofovir and emtricitabine or abacavir and lamivudine)
Number of subjects: 769
Study 29592840 — intervention group
Group type: COMPARATOR
Intervention: Ritonavir-boosted darunavir 800 mg plus two NRTIs (tenofovir and emtricitabine or abacavir and lamivudine)
Number of subjects: 769
Study 29592840 — intervention group
Group type: EXPERIMENTAL
Intervention: Doravirine
Number of subjects: 769
Study 29592840 — intervention group
Group type: COMPARATOR
Intervention: Ritonavir-boosted darunavir
Number of subjects: 769
Study 27988146 — intervention group
Group type: COMPARATOR
Intervention: Procaine benzylpenicillin and gentamicin once a day for 7 days (reference treatment)
Number of subjects: 2453
Study 27988146 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral amoxicillin twice daily and intramuscular gentamicin once a day for 7 days
Number of subjects: 2453
Study 27988146 — intervention group
Group type: EXPERIMENTAL
Intervention: Procaine benzylpenicillin and gentamicin once a day for 2 days followed by oral amoxicillin twice daily for 5 days
Number of subjects: 2453
Study 25759571 — intervention group
Group type: EXPERIMENTAL
Intervention: Poor sleep quality (Pittsburgh Sleep Quality Index >5)
Number of subjects: 1117
Study 25759571 — intervention group
Group type: COMPARATOR
Intervention: Good sleep quality (Pittsburgh Sleep Quality Index ≤5)
Number of subjects: 1117
Study 22947622 — intervention group
Group type: EXPERIMENTAL
Intervention: Generic warning label
Number of subjects: 234
Study 22947622 — intervention group
Group type: EXPERIMENTAL
Intervention: Specific more detailed warning label
Number of subjects: 234
Study 22947622 — intervention group
Group type: COMPARATOR
Intervention: No warning label
Number of subjects: 234
Study 21442523 — intervention group
Group type: EXPERIMENTAL
Intervention: Binary outcome measuring disease progression at each paired body part level
Number of subjects: 0
Study 21442523 — intervention group
Group type: EXPERIMENTAL
Intervention: Simulations performed to evaluate properties of the tests
Number of subjects: 0
Study 21442523 — intervention group
Group type: EXPERIMENTAL
Intervention: Data from a multi-center two-arm randomized clinical trial
Number of subjects: 0
Study 18997670 — intervention group
Group type: EXPERIMENTAL
Intervention: Diane(35) Diario (35 microg ethinyl-estradiol plus 2 mg cyproterone acetate)
Number of subjects: 34
Study 18997670 — intervention group
Group type: COMPARATOR
Intervention: Metformin (850 mg twice daily)
Number of subjects: 34
Study 16986086 — intervention group
Group type: EXPERIMENTAL
Intervention: PHP test
Number of subjects: 140
Study 16986086 — intervention group
Group type: EXPERIMENTAL
Intervention: Amsler grid test
Number of subjects: 140
Study 16986086 — intervention group
Group type: COMPARATOR
Intervention: Control group (healthy volunteers)
Number of subjects: 140
Study 15276895 — intervention group
Group type: EXPERIMENTAL
Intervention: Patient educators
Number of subjects: 62
Study 15276895 — intervention group
Group type: COMPARATOR
Intervention: Rheumatology faculty
Number of subjects: 62
Study 11297610 — intervention group
Group type: EXPERIMENTAL
Intervention: 22-kDa recombinant human GH (rhGH) at a dosage of 0.15 IU/kg/day for 1 week
Number of subjects: 17
Study 11297610 — intervention group
Group type: COMPARATOR
Intervention: Placebo treatment
Number of subjects: 17
Study 11297610 — intervention group
Group type: EXPERIMENTAL
Intervention: 22-kDa recombinant human GH (rhGH)
Number of subjects: 17
Study 9869946 — intervention group
Group type: EXPERIMENTAL
Intervention: Ultrarapid train stimulation
Number of subjects: 50
Study 9869946 — intervention group
Group type: COMPARATOR
Intervention: Conventional programmed electrical stimulation (PES)
Number of subjects: 50
Study 8311540 — intervention group
Group type: EXPERIMENTAL
Intervention: Diclofenac/misoprostol (50 mg/200 micrograms twice daily)
Number of subjects: 643
Study 8311540 — intervention group
Group type: COMPARATOR
Intervention: Piroxicam (10 mg twice daily)
Number of subjects: 643
Study 8311540 — intervention group
Group type: COMPARATOR
Intervention: Naproxen (375 mg twice daily)
Number of subjects: 643
Study 8311540 — intervention group
Group type: EXPERIMENTAL
Intervention: Diclofenac/misoprostol
Number of subjects: 643
Study 8311540 — intervention group
Group type: COMPARATOR
Intervention: Diclofenac/misoprostol, Piroxicam, Naproxen
Number of subjects: 643
Study 2952162 — intervention group
Group type: EXPERIMENTAL
Intervention: Heliosit‐orthodontic (light cured adhesive)
Number of subjects: 122
Study 2952162 — intervention group
Group type: COMPARATOR
Intervention: Right‐on (chemically activated adhesive)
Number of subjects: 122
Study 2952162 — intervention group
Group type: EXPERIMENTAL
Intervention: Heliosit‐orthodontic
Number of subjects: 122
Study 2952162 — intervention group
Group type: EXPERIMENTAL
Intervention: Both materials
Number of subjects: 122
Study 30245114 — intervention group
Group type: EXPERIMENTAL
Intervention: Predictive scores for NOMI based on risk factors identified (renal insufficiency, use of cardiopulmonary bypass, intra-aortic balloon pump support, reexploration for bleeding, renal replacement therapy, packed red blood cells ≥ 4 units)
Number of subjects: 8748
Study 30245114 — intervention group
Group type: COMPARATOR
Intervention: Control group (non-NOMI patients)
Number of subjects: 8748
Study 28126612 — intervention group
Group type: EXPERIMENTAL
Intervention: Immersive virtual reality (VR) curriculum for pediatric residents (n = 24)
Number of subjects: 45
Study 28126612 — intervention group
Group type: COMPARATOR
Intervention: Control group (n = 21)
Number of subjects: 45
Study 25265403 — intervention group
Group type: EXPERIMENTAL
Intervention: Theory-based video intervention
Number of subjects: 0
Study 25265403 — intervention group
Group type: COMPARATOR
Intervention: Stress management video (control)
Number of subjects: 0
Study 22555773 — intervention group
Group type: EXPERIMENTAL
Intervention: 1.4 mg/m2 eribulin mesylate alone
Number of subjects: 10
Study 22555773 — intervention group
Group type: COMPARATOR
Intervention: 0.7 mg/m2 eribulin mesylate plus 200 mg ketoconazole
Number of subjects: 10
Study 22555773 — intervention group
Group type: EXPERIMENTAL
Intervention: Both treatments
Number of subjects: 10
Study 22182758 — intervention group
Group type: EXPERIMENTAL
Intervention: Rapid Diagnostic Tests (RDTs)
Number of subjects: 102087
Study 22182758 — intervention group
Group type: EXPERIMENTAL
Intervention: Blood Microscopy
Number of subjects: 102087
Study 22182758 — intervention group
Group type: COMPARATOR
Intervention: Presumptive Diagnosis (Control)
Number of subjects: 102087
Study 18053995 — intervention group
Group type: EXPERIMENTAL
Intervention: Pen device of follitropin-alpha (Gonal-f)
Number of subjects: 100
Study 18053995 — intervention group
Group type: COMPARATOR
Intervention: Conventional syringe of follitropin-alpha (Gonal-f)
Number of subjects: 100
Study 18053995 — intervention group
Group type: EXPERIMENTAL
Intervention: Both pen device and conventional syringe of follitropin-alpha
Number of subjects: 100
Study 16150858 — intervention group
Group type: EXPERIMENTAL
Intervention: Exisulind 400 mg
Number of subjects: 281
Study 16150858 — intervention group
Group type: EXPERIMENTAL
Intervention: Exisulind 200 mg
Number of subjects: 281
Study 16150858 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 281
Study 12727766 — intervention group
Group type: EXPERIMENTAL
Intervention: LCPUFA supplementation
Number of subjects: 147
Study 12727766 — intervention group
Group type: COMPARATOR
Intervention: Non-supplementation
Number of subjects: 147
Study 12727766 — intervention group
Group type: COMPARATOR
Intervention: Breastfed children
Number of subjects: 147
Study 10898676 — intervention group
Group type: EXPERIMENTAL
Intervention: Abacavir monotherapy (200, 400, or 600 mg every 8 hours [TID] and 300 mg every 12 h [BID]) for 4 weeks
Number of subjects: 79
Study 10898676 — intervention group
Group type: EXPERIMENTAL
Intervention: Abacavir with zidovudine (200 mg TID or 300 mg BID) for 8 weeks
Number of subjects: 79
Study 10898676 — intervention group
Group type: EXPERIMENTAL
Intervention: Abacavir (300 mg BID) with zidovudine
Number of subjects: 79
Study 10898676 — intervention group
Group type: COMPARATOR
Intervention: Abacavir and zidovudine
Number of subjects: 79
Study 10898676 — intervention group
Group type: EXPERIMENTAL
Intervention: Abacavir
Number of subjects: 79
Study 8836245 — intervention group
Group type: EXPERIMENTAL
Intervention: Warm-discrimination study with innocuous heat stimuli at 36 and 43 degrees C, applied as repetitive 5-s contacts to the volar forearm.
Number of subjects: 27
Study 8836245 — intervention group
Group type: EXPERIMENTAL
Intervention: Discrimination between noxious and innocuous heat stimuli at 40 and 50 degrees C.
Number of subjects: 27
Study 8836245 — intervention group
Group type: EXPERIMENTAL
Intervention: Discrimination between tonic innocuous cold and tonic cold pain with water immersion at 20.5 degrees C and 6.02 degrees C.
Number of subjects: 27
Study 1356527 — intervention group
Group type: EXPERIMENTAL
Intervention: Human chorionic gonadotrophin (im)
Number of subjects: 257
Study 1356527 — intervention group
Group type: COMPARATOR
Intervention: Gonadotrophin releasing hormone (intranasally)
Number of subjects: 257
Study 1356527 — intervention group
Group type: COMPARATOR
Intervention: Placebo (intranasally)
Number of subjects: 257
Study 3917348 — intervention group
Group type: EXPERIMENTAL
Intervention: Serum digoxin concentrations (nil, low, high therapeutic values)
Number of subjects: 12
Study 3917348 — intervention group
Group type: COMPARATOR
Intervention: Normal subjects (control group)
Number of subjects: 12
Study 29506572 — intervention group
Group type: EXPERIMENTAL
Intervention: Electrical moxibustion
Number of subjects: 138
Study 29506572 — intervention group
Group type: COMPARATOR
Intervention: Traditional indirect moxibustion
Number of subjects: 138
Study 29506572 — intervention group
Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 138
Study 26445821 — intervention group
Group type: EXPERIMENTAL
Intervention: Radiofrequency contact‐force catheter ablation (CFCA)
Number of subjects: 56
Study 26445821 — intervention group
Group type: COMPARATOR
Intervention: Second‐generation cryoballoon ablation (CB‐AdvA)
Number of subjects: 56
Study 26445821 — intervention group
Group type: EXPERIMENTAL
Intervention: CFCA
Number of subjects: 56
Study 26445821 — intervention group
Group type: COMPARATOR
Intervention: CB‐AdvA
Number of subjects: 56
Study 24854612 — intervention group
Group type: EXPERIMENTAL
Intervention: Home monitoring with nurse visits on the 2nd, 3rd, and 5th days
Number of subjects: 84
Study 24854612 — intervention group
Group type: COMPARATOR
Intervention: Hospitalization
Number of subjects: 84
Study 23009186 — intervention group
Group type: COMPARATOR
Intervention: Ketamine alone
Number of subjects: 338
Study 23009186 — intervention group
Group type: EXPERIMENTAL
Intervention: Ketamine with adjunctive atropine
Number of subjects: 338
Study 23009186 — intervention group
Group type: EXPERIMENTAL
Intervention: Ketamine with adjunctive metoclopramide
Number of subjects: 338
Study 19749086 — intervention group
Group type: EXPERIMENTAL
Intervention: Michigan's Exemplary Physical Education Curriculum (EPEC)
Number of subjects: 1464
Study 19749086 — intervention group
Group type: COMPARATOR
Intervention: Standard PE curricula
Number of subjects: 1464
Study 17591128 — intervention group
Group type: EXPERIMENTAL
Intervention: Closed-loop anaesthesia delivery system (CLADS)
Number of subjects: 40
Study 17591128 — intervention group
Group type: COMPARATOR
Intervention: Manual control of propofol delivery
Number of subjects: 40
Study 16102546 — intervention group
Group type: EXPERIMENTAL
Intervention: Bright light therapy (BLT)
Number of subjects: 34
Study 12132062 — intervention group
Group type: EXPERIMENTAL
Intervention: IV nefopam 0.15 mg/kg in 10 mL saline
Number of subjects: 90
Study 12132062 — intervention group
Group type: EXPERIMENTAL
Intervention: IV tramadol 0.5 mg/kg in 10 mL saline
Number of subjects: 90
Study 12132062 — intervention group
Group type: COMPARATOR
Intervention: IV saline (control)
Number of subjects: 90
Study 11136320 — intervention group
Group type: EXPERIMENTAL
Intervention: Liver ultrasonography or CT
Number of subjects: 496
Study 11136320 — intervention group
Group type: EXPERIMENTAL
Intervention: Evaluation of symptoms
Number of subjects: 496
Study 11136320 — intervention group
Group type: EXPERIMENTAL
Intervention: Colonoscopy
Number of subjects: 496
Study 11136320 — intervention group
Group type: EXPERIMENTAL
Intervention: CEA measurement
Number of subjects: 496
Study 11136320 — intervention group
Group type: EXPERIMENTAL
Intervention: Chest radiography
Number of subjects: 496
Study 11136320 — intervention group
Group type: EXPERIMENTAL
Intervention: Physical examination
Number of subjects: 496
Study 11136320 — intervention group
Group type: EXPERIMENTAL
Intervention: Other modalities
Number of subjects: 496
Study 11136320 — intervention group
Group type: EXPERIMENTAL
Intervention: Curative treatment for recurrence
Number of subjects: 496
Study 11136320 — intervention group
Group type: EXPERIMENTAL
Intervention: Diagnostic procedures for curative resected recurrence
Number of subjects: 496
Study 11136320 — intervention group
Group type: EXPERIMENTAL
Intervention: Ultrasonography and colonoscopy
Number of subjects: 496
Study 11136320 — intervention group
Group type: EXPERIMENTAL
Intervention: Routine follow-up by CEA measurement, chest radiography, and physical examination
Number of subjects: 496
Study 9542781 — intervention group
Group type: EXPERIMENTAL
Intervention: CyA‐NF (Sandimmun Neoral)
Number of subjects: 15
Study 9542781 — intervention group
Group type: COMPARATOR
Intervention: CyA‐ST
Number of subjects: 15
Study 7917935 — intervention group
Group type: EXPERIMENTAL
Intervention: Serum neuron-specific enolase (S-NSE)
Number of subjects: 27
Study 7917935 — intervention group
Group type: COMPARATOR
Intervention: Serum lactate dehydrogenase (S-LDH)
Number of subjects: 27
Study 3277562 — intervention group
Group type: EXPERIMENTAL
Intervention: Cefuroxime axetil, 250 mg orally every 12 hours
Number of subjects: 61
Study 3277562 — intervention group
Group type: EXPERIMENTAL
Intervention: Cefuroxime axetil, 500 mg orally every 12 hours
Number of subjects: 61
Study 3277562 — intervention group
Group type: COMPARATOR
Intervention: Cefaclor, 500 mg orally every eight hours
Number of subjects: 61
Study 31931512 — intervention group
Group type: EXPERIMENTAL
Intervention: Deferred grazing (intermittent grazing)
Number of subjects: 6
Study 31931512 — intervention group
Group type: EXPERIMENTAL
Intervention: Grazing exclusion
Number of subjects: 6
Study 31931512 — intervention group
Group type: COMPARATOR
Intervention: Control (traditional continuous grazing)
Number of subjects: 6
Study 29753297 — intervention group
Group type: EXPERIMENTAL
Intervention: Nurse practitioner care coordination
Number of subjects: 200
Study 29753297 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 200
Study 28139192 — intervention group
Group type: EXPERIMENTAL
Intervention: Tourniquet inflation during cementation
Number of subjects: 40
Study 28139192 — intervention group
Group type: COMPARATOR
Intervention: No tourniquet during cementation
Number of subjects: 40
Study 25600123 — intervention group
Group type: EXPERIMENTAL
Intervention: Cefazolin 1 day, placebo days 2 to 5
Number of subjects: 0
Study 25600123 — intervention group
Group type: EXPERIMENTAL
Intervention: Cefazolin days 1 to 5
Number of subjects: 0
Study 25600123 — intervention group
Group type: EXPERIMENTAL
Intervention: Gentamicin and clindamycin 1 day, placebo days 2 to 5
Number of subjects: 0
Study 25600123 — intervention group
Group type: EXPERIMENTAL
Intervention: Gentamicin and clindamycin days 1 to 5
Number of subjects: 0
Study 25600123 — intervention group
Group type: COMPARATOR
Intervention: Control group (placebo)
Number of subjects: 0
Study 23499607 — intervention group
Group type: EXPERIMENTAL
Intervention: School-located vaccination against influenza (SLV-I)
Number of subjects: 13561
Study 23499607 — intervention group
Group type: COMPARATOR
Intervention: No vaccination (control)
Number of subjects: 13561
Study 21572151 — intervention group
Group type: EXPERIMENTAL
Intervention: ETN 25 mg twice a week with 6‐8 mg/week MTX (E+M group)
Number of subjects: 151
Study 21572151 — intervention group
Group type: COMPARATOR
Intervention: ETN alone (E group)
Number of subjects: 151
Study 18288617 — intervention group
Group type: EXPERIMENTAL
Intervention: Rebamipide (100 mg t.i.d)
Number of subjects: 453
Study 18288617 — intervention group
Group type: COMPARATOR
Intervention: Sucralfate (1.0 t.i.d)
Number of subjects: 453
Study 17027406 — intervention group
Group type: EXPERIMENTAL
Intervention: Chondroplasty
Number of subjects: 33
Study 17027406 — intervention group
Group type: EXPERIMENTAL
Intervention: Microfracture
Number of subjects: 33
Study 17027406 — intervention group
Group type: COMPARATOR
Intervention: Osteochondral Autograft Transplantation (OAT)
Number of subjects: 33
Study 14583577 — intervention group
Group type: EXPERIMENTAL
Intervention: Fludarabine
Number of subjects: 15
Study 10985711 — intervention group
Group type: EXPERIMENTAL
Intervention: Percutaneous or surgical revascularization
Number of subjects: 379
Study 10985711 — intervention group
Group type: COMPARATOR
Intervention: Nondiabetic patients
Number of subjects: 379
Study 10985711 — intervention group
Group type: EXPERIMENTAL
Intervention: Diabetic patients
Number of subjects: 379
Study 10985711 — intervention group
Group type: EXPERIMENTAL
Intervention: Diabetes as a predictor of mortality
Number of subjects: 379
Study 8628335 — intervention group
Group type: EXPERIMENTAL
Intervention: Fish-oil preparation (2.7 g of n-3 fatty acids daily)
Number of subjects: 78
Study 8628335 — intervention group
Group type: COMPARATOR
Intervention: Placebo capsules (daily)
Number of subjects: 78
Study 8628335 — intervention group
Group type: EXPERIMENTAL
Intervention: Fish-oil preparation
Number of subjects: 78
Study 8628335 — intervention group
Group type: COMPARATOR
Intervention: Placebo capsules
Number of subjects: 78
Study 1591093 — intervention group
Group type: EXPERIMENTAL
Intervention: Tamoxifen
Number of subjects: 46
Study 1591093 — intervention group
Group type: COMPARATOR
Intervention: Tamoxifen plus prednisolone
Number of subjects: 46
Study 29489721 — intervention group
Group type: EXPERIMENTAL
Intervention: 1.2 g·kg‐1 LMW (maltodextrin/dextrose/fructose)
Number of subjects: 10
Study 29489721 — intervention group
Group type: EXPERIMENTAL
Intervention: 1.2 g·kg‐1 HMW (Vitargo)
Number of subjects: 10
Study 29489721 — intervention group
Group type: COMPARATOR
Intervention: 0.066 g·kg‐1 PLA (noncaloric flavoring)
Number of subjects: 10
Study 31361175 — intervention group
Group type: EXPERIMENTAL
Intervention: Physical exercise (balance, flexibility, strength training)
Number of subjects: 175
Study 31361175 — intervention group
Group type: EXPERIMENTAL
Intervention: Music interventions (singing, listening to music, playing instruments)
Number of subjects: 175
Study 31361175 — intervention group
Group type: COMPARATOR
Intervention: Treatment as usual (control group)
Number of subjects: 175
Study 29954223 — intervention group
Group type: EXPERIMENTAL
Intervention: Nonexperimental (NE) designs
Number of subjects: 0
Study 29954223 — intervention group
Group type: COMPARATOR
Intervention: Randomized experiment
Number of subjects: 0
Study 29954223 — intervention group
Group type: EXPERIMENTAL
Intervention: WSC designs with independent and dependent benchmark and NE arms
Number of subjects: 0
Study 27072963 — intervention group
Group type: EXPERIMENTAL
Intervention: (125)I seed implantation
Number of subjects: 224